Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE

Lancet Diabetes Endocrinol. 2024 Apr 24:S2213-8587(24)00092-5. doi: 10.1016/S2213-8587(24)00092-5. Online ahead of print.
No abstract available